- Fuchsberger, N – HAJNICKÁ, Valéria – BARTÍKOVÁ, Pavlína; Patent Number: US 07439229, Patent Assignee: Evolutec Limited: Cytokine activity regulator molecules from tick salivary glands. U.S. Patent and Trademark Office.
- NEMČOVIČOVÁ, Ivana – Benedict, CA – Zajonc, DM, Verma, S – U.S. patent US2017088600-A1; Composition for designing compound, protein or peptide that interacts with TNF-related apoptosis inducing ligand (TRAIL)-R2 receptor, comprises TRAIL-R2 receptor or its fragment bound to ligand in crystalline form.
- NEMČOVIČOVÁ, Ivana – Benedict, CA – Zajonc, DM – U.S. patent US2014134647-A1; Composition useful in antiviral drug for e.g. providing antiinflammatory response, comprises TRAIL-R2 receptor or fragment of TRAIL-R2 receptor bound to ligand in crystalline form.
- Rajčáni, J – Matis, J – Leško, J – Leššo, J – KÚDELOVÁ, Marcela. Author’s certificate of invention No. 265536, granted by the Federal Office for Inventions: Subunit vaccine against recurrent herpes and method of its preparation.
- BARTOŠOVÁ Mária – ŠKULTÉTY Ľudovít – Polakovič Milan – Molnár Tomáš – Adamíková Jana – Antošová Monika. Owner/co-owner: Slovak University of Technology in Bratislava/Biomedical Center of the Slovak Academy of Sciences, v. v. i. Patent number: 289057: Method for the chromatographic purification of recombinant human erythropoietin (2023).
- License granted: Antigens for diagnosing Q fever and chlamydial infections (2023, non-exclusive license). Licensee: MultiplexDX, s. r. o., Bratislava. Contact person for BMC SAS: Ing. Ľudovít Škultéty, DrSc. https://www.crz.gov.sk/zmluva/7393606/
- Škultéty Ľudovít – Flores-Ramírez Gabriela. Registered invention: Live culture of Coxiella burnetii strain RSA439 growing on axenic medium (2021, non-exclusive license – vaccine development)
- License agreement with BioLegend, Inc., California, USA (2020, non-exclusive license). Applies to the use of hybridoma cell lines for the production and global sale of monoclonal antibodies specific to the tumor angiogenesis biomarker endosialin for research purposes. https://www.crz.gov.sk/4948728/
- The antibodies covered by the license were prepared at the BMC SAS Research Institute and are described in the following publications:
- Kontsekova S, Ohradanova Repic A, Polcicova K, Tuomaala P, Pastorek J, Pastorekova S, Parkkila S, Barathova M. Novel monoclonal antibodies specific for CTLD-SSC and sialomucin domains of endosialin, a mural cell marker of tumor vasculature. Int J Oncol. 2012 Oct;41(4):1365-72. doi: 10.3892/ijo.2012.1566. Epub 2012 Jul 23. PMID: 22824847.
- Kontsekova S, Polcicova K, Takacova M, Pastorekova S. Endosialin: molecular and functional links to tumor angiogenesis. Neoplasma. 2016;63(2):183-92. doi: 10.4149/202_15090N474. PMID: 26774137
- The antibodies covered by the license were prepared at the BMC SAS Research Institute and are described in the following publications:
- License agreement between BMC SAS and BioScience Slovakia, s.r.o., Slovak Republic, for the use of part of the patent rights to the MN/CA IX invention. (2017)
- License agreement between BMC SAS and WILEX AG, Germany, for the use of part of the patent rights to the MN/CA IX invention. (2017)
- License agreement with MABPRO, s.r.o., Slovak Republic, for the use of part of the patent rights to the MN/CA IX invention. (2017)